FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fins de pesquisa apenas. Leia o disclaimer completo →

Pesquisa/Peptide Therapy Trial Examines Impact of CagriSema on Blood Levels of Common Medications
Voltar à Biblioteca de Pesquisa

Peptide Therapy Trial Examines Impact of CagriSema on Blood Levels of Common Medications

May 25, 2026
Share
Pesquisa Emergente

Baseado em pesquisa emergente. Esses achados são promissores, mas requerem validação adicional.

Sobre esta Análise

Este artigo é uma síntese assistida por inteligência artificial de um item noticiário ou lista de ensaios clínicos recentemente publicado. É intenção fornecer uma visão rápida e acessível para a comunidade de pesquisa em peptídeos. Para obter a precisão completa, sempre consulte o

Peptide Therapy Trial Examines Impact of CagriSema on Blood Levels of Common Medications

A recent study conducted by Novo Nordisk A/S has completed its Phase 1 clinical trial, exploring how a combination therapy called CagriSema affects blood levels of atorvastatin and warfarin in individuals with excess body weight. This research is crucial for understanding the potential interactions between peptides like semaglutide and cagrilintide and other medications used to manage cardiovascular health.

Background

CagriSema combines two peptide therapies: cagrilintide, an amylin analog that helps control appetite and reduces food intake, and semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist known for its weight management benefits. Both peptides are commonly used in the treatment of obesity and type 2 diabetes but have not been extensively studied for their impact on other medications.

The study was initiated to address concerns about how these new therapies might interact with existing drugs, particularly those that individuals with excess body weight often take, such as atorvastatin (a cholesterol-lowering medication) and warfarin (an anticoagulant). Understanding the interaction between CagriSema and these common medications is essential for ensuring patient safety and optimizing treatment outcomes.

Key Details

The trial involved participants with obesity who were already taking atorvastatin or warfarin. Researchers measured blood levels of these drugs before introducing CagriSema to determine if there was any change once the combination therapy began. The study also investigated whether the injection site for CagriSema influenced its concentration in the bloodstream, which could have implications for how it is administered.

Participants underwent regular monitoring over an 8-month period, allowing researchers to collect comprehensive data on drug interactions and pharmacokinetics. This long-term observation helps establish a more accurate picture of how CagriSema affects blood levels of atorvastatin and warfarin throughout the course of treatment.

Key Takeaways

  • Interaction Analysis: The study provides critical insights into how CagriSema interacts with common medications used by individuals managing obesity, such as atorvastatin and warfarin.
  • Pharmacokinetics Assessment: Detailed analysis of blood levels before and after the introduction of CagriSema helps researchers understand the pharmacological effects more thoroughly.
  • Injection Site Impact: Researchers explored whether different injection sites influence how much of the drug is absorbed into the bloodstream, offering practical guidance for administration methods.
  • Long-Term Observations: An 8-month study duration ensures that long-term trends in medication levels and patient response can be accurately assessed.

What This Means

This trial contributes significantly to our understanding of peptide therapy's broader implications beyond weight management. As more patients adopt these therapies, it is crucial to ensure they do not interfere with other necessary medications. The findings from this study will help healthcare providers make informed decisions about treatment regimens and potentially adjust dosages or administration methods based on the interaction profiles identified.

For researchers in the peptide community, these results highlight the importance of considering drug interactions when developing new treatments for obesity and metabolic disorders. This research underscores the need for ongoing investigation into how peptides like semaglutide and cagrilintide interact with other medications to ensure safe and effective treatment options moving forward.

---

Source: ClinicalTrials.gov — Published 2026-05-19

This article is for informational purposes only and does not constitute medical advice.

Nota do Editor

Esta análise foi gerada usando ferramentas de inteligência artificial e revisada pela equipe editorial da Peptide Contacts. Embora busquemos a precisão, o conteúdo gerado por inteligência artificial pode conter erros ou omissões. Encorajamos os leitores a revisar o fonte original para detalhes completos, metodologia e dados.

A Peptide Contacts fornece resumos de pesquisa curados para fins informativos apenas. Este conteúdo não constitui conselhos médicos. Sempre consulte um provedor de saúde qualificado antes de tomar qualquer decisão relacionada à saúde.

Comments

Sign in to join the discussion

Este artigo foi gerado usando inteligência artificial e pode conter inaccuracy. É fornecido para fins informativos apenas e não constitui conselhos médicos. Sempre verifique as informações com a fonte original e consulte um provedor de saúde qualificado antes de tomar qualquer decisão relacionada à saúde.